LLY

1,005.81

-0.75%↓

JNJ

229.58

-0.19%↓

ABBV

212.13

-1.06%↓

UNH

385.46

-1.93%↓

AZN

187.32

+0.83%↑

LLY

1,005.81

-0.75%↓

JNJ

229.58

-0.19%↓

ABBV

212.13

-1.06%↓

UNH

385.46

-1.93%↓

AZN

187.32

+0.83%↑

LLY

1,005.81

-0.75%↓

JNJ

229.58

-0.19%↓

ABBV

212.13

-1.06%↓

UNH

385.46

-1.93%↓

AZN

187.32

+0.83%↑

LLY

1,005.81

-0.75%↓

JNJ

229.58

-0.19%↓

ABBV

212.13

-1.06%↓

UNH

385.46

-1.93%↓

AZN

187.32

+0.83%↑

LLY

1,005.81

-0.75%↓

JNJ

229.58

-0.19%↓

ABBV

212.13

-1.06%↓

UNH

385.46

-1.93%↓

AZN

187.32

+0.83%↑

Accueil・Liste d'Actions・Novo Nordisk A-S

Novo Nordisk A-S

Ouvert

SecteurSoins de santé

44.86 0.52

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

44.2

Max

44.98

Chiffres clés
By Trading Economics
Revenu	22B 49B
Ventes	18B 97B
P/E Moyenne du Secteur	10.791 51.415
BPA	6.63
Rendement du dividende	3.88
Marge bénéficiaire	50.15
Employés	67,900
EBITDA	32B 69B

Recommandations
By TipRanks
Recommandations	Neutre
Prévisions sur 12 Mois	-2.89% downside

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	3.88% 2.34%

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	8.9B 206B
Ouverture précédente	44.34
Clôture précédente	44.86

Sentiment de l'Actualité

By Acuity

50%

174 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

62.63 / 69.23 Support & Résistance

Novo Nordisk A-S Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 mai 2026, 15:48 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence

6 mai 2026, 07:30 UTC

Résultats

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6 mai 2026, 06:19 UTC

Résultats

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

18 mai 2026, 13:10 UTC

Market Talk

Résultats

Novo Nordisk Report Shows Bright Spots Amid Price Pressure -- Market Talk

12 mai 2026, 12:05 UTC

Actions en Tendance

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 mai 2026, 10:51 UTC

Actions en Tendance

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 mai 2026, 09:42 UTC

Résultats

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

12 mai 2026, 09:08 UTC

Actions en Tendance

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

11 mai 2026, 20:30 UTC

Résultats

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

7 mai 2026, 09:30 UTC

Résultats

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 mai 2026, 12:36 UTC

Résultats

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 mai 2026, 10:53 UTC

Actions en Tendance

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 mai 2026, 10:12 UTC

Résultats

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 mai 2026, 09:58 UTC

Résultats

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6 mai 2026, 09:35 UTC

Actions en Tendance

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 mai 2026, 08:13 UTC

Market Talk

Résultats

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6 mai 2026, 07:43 UTC

Market Talk

Résultats

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6 mai 2026, 07:00 UTC

Résultats

Novo Nordisk Shares Rise 5.5% After 1Q Results

6 mai 2026, 06:34 UTC

Résultats

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6 mai 2026, 06:26 UTC

Résultats

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6 mai 2026, 06:26 UTC

Résultats

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6 mai 2026, 06:24 UTC

Résultats

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6 mai 2026, 06:20 UTC

Résultats

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6 mai 2026, 06:19 UTC

Résultats

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6 mai 2026, 06:13 UTC

Résultats

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6 mai 2026, 06:13 UTC

Résultats

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6 mai 2026, 06:12 UTC

Résultats

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6 mai 2026, 05:43 UTC

Résultats

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

6 mai 2026, 05:42 UTC

Résultats

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

6 mai 2026, 05:40 UTC

Résultats

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

Comparaison

Variation de prix

Novo Nordisk A-S prévision

Objectif de Prix

By TipRanks

-2.89% baisse

Prévisions sur 12 Mois

Moyen 43 USD -2.89%

Haut 47 USD

Bas 40 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

62.63 / 69.23Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

174 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.